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ABSTRACT
As nanoparticles (NPs) are cleared via phagocytes of the mono-
nuclear phagocyte system (MPS), we hypothesized that the
function of circulating monocytes and dendritic cells (MO/DC) in
blood can predict NP clearance (CL). We measured MO/DC
phagocytosis and reactive oxygen species (ROS) production in
mice, rats, dogs, and patients with refractory solid tumors.
Pharmacokinetic studies of polyethylene glycol (PEG)-encapsulated
liposomal doxorubicin (PEGylated liposomal doxirubicin [PLD]),
CKD-602 (S-CKD602), and cisplatin (SPI-077) were performed at
themaximum tolerated dose. MO/DC functionwas also evaluated
in patients with recurrent epithelial ovarian cancer (EOC) admin-
istered PLD. Across species, a positive association was ob-
served between cell function and CL of PEGylated liposomes. In
patients with EOC, associations were observed between PLD
CL and phagocytosis (R2 5 0.43, P5 0.04) and ROS production
(R2 5 0.61, P 5 0.008) in blood MO/DC. These findings suggest
that probes of MPS functionmay help predict PEGylated liposome
CL across species and PLD CL in patients with EOC.
Introduction
Nanoparticles (NPs), which include polyethylene glycol
(PEG)-encapsulated (PEGylated) liposomes, are novel drug-
delivery platforms that have the potential to improve tumor
drug exposure and reduce accumulation in normal tissues
more so than their small-molecule counterparts (Zamboni and
Tonda, 2000; Zamboni, 2005, 2008). The pharmacokinetics
(PK) of NPs are dependent upon the carrier and not the drug
encapsulated within the carrier until the drug gets released
from the carrier (Papahadjopoulos et al., 1991; Park et al.,
2004; Zamboni, 2005, 2008). The drug that remains encapsu-
lated within NPs is an inactive prodrug, and thus the drug
must be released from the carrier to be active. After the drug
is released from the carrier, the PK disposition of the drug will
be the same as that following administration of the noncarrier
form of the drug (Zamboni and Tonda, 2000; Zamboni, 2005,
2008).
The PK disposition of PEGylated liposomal formulations of
CKD602 (S-CKD602), doxorubicin (Doxil; Janssen (of J&J),
Titusville, NJ), and cisplatin (SPI-077), have been evaluated
in preclinical models and patients (Lee et al., 2000; Gabizon
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et al., 2003; Zamboni et al., 2007). The ability to extrapolate
animal data to predict PK parameters in humans is an
essential step in drug development (Gabizon et al., 2008). We
have previously explored the use of allometric scaling to
predict the PK of PEGylated liposomal agents across species
(Caron et al., 2011). Our study indicated that while a relation-
ship exists between species body weight and clearance (CL),
there is considerable variability in PK among species, par-
ticularly when scaled by conventional and nonconventional
parameters. Thus, the development of new methods of sca-
ling and/or measures of NP interaction at the biologic level
are warranted to further explore the variability observed in
NP PK.
Studies suggest that the significantly high and clinically
relevant interpatient variability in the PK and pharmacody-
namic (PD) disposition of NP anticancer agents is related to
the function of monocytes and dendritic cells (MO/DC) of the
mononuclear phagocyte system (MPS) (Zamboni et al., 2011a;
Zamboni et al., 2011b). PEGylated and non-PEGylated nano-
particle agents are cleared via the MPS, but PEGylated nano-
particle agents are cleared at a slower rate because of delayed
and/or reduced recognition by the MPS (Dobrovolskaia et al.,
2008; Caron et al., 2012). The MPS is defined as a group of
cells having the ability to ingest large numbers of particles
(Hume et al., 2002). These cells (comprisingMO/DC circulating
in the blood, fixed macrophages of various connective tissues,
Kupffer cells in the liver, andmacrophages in the lymph nodes,
bone marrow, and spleen) serve as a potential CL pathway for
NPs (Lichanska et al., 1999; Hume et al., 2002; Dobrovolskaia
et al., 2008). We have previously reported a significant relation-
ship between the PK and PD of S-CKD602 and changes in
circulating monocyte numbers and absolute neutrophil count
(Zamboni et al., 2011b). The results of our previous study
suggest that monocytes are more sensitive to toxic effects of
S-CKD602 compared with neutrophils and that the increased
sensitivity appears to be related to the liposomal formulation
and not the small molecule drug, CKD-602, encapsulated inside
the liposome. Thus, blood monocytes may play a key role or be
a surrogate marker for NP CL in patients.
Epithelial ovarian cancer (EOC) is a disease characterized
by large numbers of peritoneal MO and macrophages, the
primary cells of the MPS (Bookman, 2005). As a result of high
relapse rates several chemotherapeutic strategies have been
developed for this patient population. PEGylated liposomal
doxorubicin (PLD) is frequently used second- and third-line
for the treatment of recurrent EOC and is one of the few U.S.
Food and Drug Administration–approved NPs currently
available (Caron et al., 2012). However, in the second-line
treatment of platinum-refractory EOC, PLD achieves overall
response rates of only 14 to 20% (Ozols et al., 1997; Bookman,
2005). Moreover, there is significant variability in the PK and
PD associated with PLD. Therefore, some patients are much
more likely to receive a nonefficacious or toxic, particularly
palmar-plantar erythrodysethesia (PPE), response (La-Beck
et al., 2011). Thus, there is a compelling need to guide PLD
dosing to improve the response rate and quality of life for
women with EOC (Amantea et al., 1997; Gabizon et al., 1994,
2008; Sidone et al., 2007; Uziely et al., 1995).
One approach to improve the treatment of patients is to
identify and use a phenotypic probe to individualize therapy
(van der Bol et al., 2010). A phenotypic probe is a test or agent
than can be administered to a patient as an indicator of the
PK and/or PD of a drug, which can then be used to individu-
alize therapy. Phenotypic probes measuring cellular function
in blood could be used to evaluate the relationship between
activity of the MPS and the effect on NP PK and PD in a rel-
atively noninvasive fashion. The objective of this study was
to evaluate phenotypic probes of MPS function in blood as
predictors of PK and PD of PEGylated liposomal agents in
animal models and patients. The function of MO/DC and poly-
morphonuclear leukocytes (PMNs) of the MPS in blood was
evaluated using phagocytosis and reactive oxygen species (ROS)
production.
Materials and Methods
The preclinical studies were approved by the University of North
Carolina’s Institutional Animal Care andUse Committee. The clinical
studies were approved by the Committee for the Rights of Human
Subjects (Institutional ReviewBoard) at theUniversity of NorthCarolina
at Chapel Hill. All patients were advised of the purpose, procedures, and
associated risks and gave written informed consent.
Phenotypic and PK Studies in Preclinical Animal Models
and Patients
Phenotypic studies of MPS function and PK of PEGylated liposomal
agents were performed inmice, rats, dogs and patients with refractory
solid tumors as part of clinical phase I studies (MeerumTerwogt et al.,
2000, 2002; Gabizon et al., 2003, 2008; Zamboni et al., 2007). A blood
sample was obtained using a sodium heparinized tube from each of
the species to assess MO/DC phagocytosis and ROS production using
flow cytometry (methods are detailed in EOC clinical study). Blood
samples were obtained prior to administration of liposomal agents in
triplicate in each species.
S-CKD602, PLD, and SPI-077 were administered to SCID mice,
Sprague-Dawley rats, beagle dogs, and as part of phase I clinical
studies as described previously (Lee et al., 2000; Meerum Terwogt
et al., 2000, 2002; Gabizon et al., 2003, 2008; Zamboni et al., 2007).
Serial blood sampling times and analytical methods used to deter-
mine sum total nanoparticle concentrations are also provided in these
previously published studies. The concentration versus time data
were imported into Phoenix WinNonlin Version 6.1 (Pharsight Corp.,
Mountain View, CA) and a noncompartmental analysis was used to
determine CL in each species.
PLD PK and PD Studies in EOC
Inclusion Criteria. Women receiving PLD as part of their standard-
of-care treatment of recurrent EOC were eligible for enrollment in this
study. Doxil, doxorubicin, encapsulated in STEALTH liposomes, was
purchased from Janssen and used in all patients. Patients had to be
$18 years of age and have a documented hysterectomy or negative preg-
nancy test.
Clinical Study Design. Baseline characteristics and treatment
regimens of the 10 women enrolled are listed in Table 1. Patients were
administered standard premedications, including 10 mg of dexa-
methasone, 25mg of diphenhydramine, 20mg of famotidine, and 8mg
of ondansetron, all intravenous 1, 30minutes prior to PLD. Patients
were administered PLD at 40mg/m2 alone or PLD at 30mg/m2 i.v. 1,
over approximately 1 hour in combination with carboplatin infused
intravenously 1 over 30 minutes at a dose to achieve area under the
curve (AUC) 5 5 (Calvert equation). Serial blood PK samples were
obtained at baseline prior to the administration of PLD or PLD with
carboplatin; at the end of infusion; and 1, 3, 24, 48, 72, 96, 192, and
672 hours after the administration of PLD. Plasma was processed
immediately, and the encapsulated and released components of PLD
were separated using solid phase separation methods as described
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previously (Zamboni and Tonda, 2000; Zamboni et al., 2007, 2009).
Noncompartmental analysis was performed using Phoenix WinNonlin
Version 6.1 to calculate PK parameters (Table 2).
Blood (3 ml) was obtained at baseline, 48, 72, and 96 hours to test
the function of MO/DC. At each visit, vital signs were obtained, phy-
sical examinations and blood work was performed at the discretion of
the individual physician, and patients were asked about any adverse
symptoms they experienced, including but not limited to nausea/
vomiting, PPE, neuropathy, and stomatitis. Grade of toxicity was
determined by the National Cancer Institute’s Common Terminology
Criteria for Adverse Events (NCI CTCAE, version 4.03). Patients
were followed until disease progression or toxicity necessitated dis-
continuation of PLD. Progression-free survival (PFS) was determined
by Response Evaluation Criteria in Solid Tumors (version 1.1).
Phenotypic Probes. Innate immune function (phagocytosis and
ROS production) of peripheral blood monocytes and PMNs was
assessed by flow cytometry. Initially, data were used to determine
whether there was a relationship between cellular function and PK
among species. A single 1-ml blood sample was taken from each species
(n5 3) used in the PK studies to test cellular function. Data were then
used to assess possible correlations between cellular function (phago-
cytosis and ROS production) and PK (CL of PLD) and PD (PFS and
PPE) of PLD in women with recurrent EOC. Studies of MPS function
prior to the administration of PLD in each patient were used to predict
PLDPK and PD. Additionally, the changes in cellular phagocytosis and
ROS over time were assessed within and between all patients.
Flow cytometry was performed in the University of North Carolina
Flow Cytometry Core Facility using a DakoCyan flow cytometer, and
data were analyzed using FlowJo software (version 7.6.5.). For both
the phagocytosis and ROS assays, MO/DC and PMN populations were
gated based on light scatter properties (forward scatter versus side
scatter) and subsequently plotted for histogram analysis (Supple-
mental Fig. 1). The proportion of positive cells (i.e., cells that exhibit
fluorescence) was determined as those events, which shifted to the
right out of the “negative” region on the fluorescence intensity scale.
Mean fluorescent intensity (MFI) of the positive cell population served
as an index of phagocytic or ROS activity.
Phagocytosis Assay. Twenty microliters of fluorescein isothiocyanate–
labeled opsonizedEschericia coli bacteria bioparticles (1 108 particles/
ml) (Orpegen Pharma, San Diego, CA) were added to 100 ml of whole
blood and incubated for 10 minutes at 37°C. Additional samples kept
on ice (0°C) served as a negative control. After incubation, 100 ml of
Trypan blue was added to quench extracellular fluorescence. Phago-
cytic activity (number of bacteria internalized per cell) was quantified
as the MFI of the “positive” cells.
ROS Production Assay. ROSwas assessed inMO/DC in response
to no stimuli and to a variety of stimulants, including opsonized
nonfluorescent E. coli as a phagocytic stimulus, N-formyl-methionine-
leucine-phenylalanine as a physiologic peptide, phorbol 12-myristate
13-acetate (PMA) a synthetic ester, and phosphate-buffered saline
as a control (no stimulus; baseline measurement). Following a 10-
minute exposure to the stimulus, nonfluorescent dihydrorhodamine
123 (Orpegen Pharma, San Diego, CA) was added to the samples
as a fluorogenic substrate, which, following intracellular oxidation
was converted to fluorescent rhodamine 123. MFI of rhodamine 123
fluorescence served as a quantitative measure of intracellular oxidative
activity.
Statistics. All statistical analyses were performed using SAS
version 9.2 (Cary, NC) software. Simple linear regression was used to
explore the linear relationship between two continuous variables,
including the relationship between MO/DC or PMN cellular function
and PK (CL) or PD (PPE grade and PFS). The coefficient of deter-
mination, R2 was used to measure the linear association between
PK/PD outcomes and cellular function. The relationship between CL
and phagocytosis was evaluated using multiple linear regression,
including a term for treatment type (PLD versus PLD1 carboplatin).
A Kruskal-Wallis test was used to test for differences in median MFI
between patients and within patients over the course of cycle 1. A Cox
proportional hazards model, using progression-free survival as the
outcome variable and phagocytosis as a covariate, was used to estimate
predicted progression-free survival at differing levels of phagocytosis.
The value of a was set at 0.05 for all statistical tests, and all P values
are two-sided.
Results
Relationship between Cellular Function and PEGy-
lated Liposome PK in Preclinical Models and Patients
with Refractory Solid Tumors. The relationship between
phenotypic probes of MPS function and PK of PEGylated
liposomal agents was evaluated in preclinical tumor models
and in patients with refractory solid tumors as part of phase I
studies of PEGylated liposomal doxorubicin (Doxil; PLD),
CKD-602 (S-CKD602), and cisplatin (SPI-077). There was
a direct linear relationship between MPS activity and the CL
of PEGylated liposomes across mice, rats, dogs, and humans.
The average mean fluorescence intensity in the MO/DC
population following the phagocytosis assay in the four
species evaluated was correlated with CL of PLD (R2 5 0.95),
S-CKD602 (R2 5 0.99), and SPI-077 (R2 5 0.73) as shown in
Fig. 1A. There was a similar trend observed when comparing
the production of ROS across species without any stimulus
(baseline) with CL of PLD (R2 5 0.77), S-CKD602 (R2 5 0.77),
and SPI-077 (R2 5 0.66) (Fig. 1B). The relationship was also
seen between production of ROS when stimulated with PMA
TABLE 1
Baseline characteristics of patients enrolled in the study
Patient Age Race Weight BSA Chemotherapy
years kg
1 63 C 54 1.63 PLD
2 51 C 73 1.9 PLD
3 57 C 71 1.78 PLD
4 67 C 89 1.96 PLD + carboplatin
5 76 C 91 1.91 PLD
6 51 C 72 1.84 PLD + carboplatin
7 53 C 94 1.94 PLD + carboplatin
8 75 C 48 1.46 PLD
9 44 C 77 1.91 PLD + carboplatin
10 52 AA 116 2 PLD
Mean 6 S.D.
or Total
59 6 10.9 9 C, 1AA 78 6 20 1.8 6 0.2 6 PLD alone 4
PLD + carboplatin
AA, African American; BSA, body surface area; C, Caucasian.
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and CL of PLD (R2 5 0.83), S-CKD602 (R2 5 0.84), and SPI-
077 (R2 5 0.69).
Phenotypic Probes Predict PLD PK in Patients with
EOC. The relationship between phenotypic probes of MPS
function and PLD PK was evaluated in patients with EOC.
On day 1 of the study, phagocytosis and ROS production
were assessed in MO/DC prior to the start of the PLD
infusion in patients with EOC (n5 10). A linear relationship
(R2 5 0.43, P 5 0.04) was found between MFI of the
phagocytic cells and PLD CL for all patients, shown in Fig. 2A.
A relationship between MFI of ROS production without
stimulus at baseline and PLD CL for all patients was also
observed, as shown in Fig. 2B (R2 5 0.61, P 5 0.008). The
relationship between the MPS function is more significant
in patients treated with PLD alone (R2 5 0.57 and 0.61 for
phagocytosis and production of ROS without stimulus, re-
spectively) (Fig. 2, C and D).
There was also a relationship between the ROS probe with
the addition of a stimulant, and PLD CL in all patients at
baseline (Table 3). The only stimulant that did not show
a strong relationship in all patients was PMA (R2 5 0.23).
PMAwas also the only probe that had lower association in the
PLD alone versus PLD 1 carboplatin group. However, the
other oxidative burst stimulants performed similarly to the
phagocytosis probe and also demonstrated stronger relation-
ships in the cohort of patients which received PLD alone
versus PLD 1 carboplatin.
A multiple linear regression model was also used to exa-
mine the relationship between phagocytosis and doxorubicin
clearance, adjusting for treatment. The model had doxorubi-
cin clearance as the dependent variable and phagocytosis
and treatment (an indicator variable for PLD or PLD plus
carboplatin) as the independent variables. This model, which
results in two intercepts (intercept for PLD alone 5 b0 and
intercept for PLD plus carboplatin 5 b0 1 btreatment) and
a common slope (bphagocytosis), suggests a positive linear asso-
ciation between phagocytosis and CL of PLD (bphagocytosis 5
0.04, P5 0.07) where patients with higher MPS function have
a higher CL of PLD (Fig. 3). Patients on PLD plus carboplatin
(dotted regression line) had somewhat lower doxorubicin clear-
ance compared with patients on PLD only (solid regression line);
however, the treatment effect was not significant (btreatment 5
6.06, P 5 0.38).
The correlation between either phagocytosis or ROS pro-
duction in PMNs and PLD CL failed to reach statistical sig-
nificance in either the total patient population or subpopulations,
suggesting that PMN are not involved in the PK of PLD. In
the study, 87.4 6 10.9% of gated MO/DC in patients tested
positive to the phagocytosis or ROS probe. Therefore, differences
inMFI between patients were due to cellular function variability
and not the ability of the assay to detect positive events.
Cellular Function over Time in Patients with EOC.
The cellular function of MO/DC and PMNs was also assessed
over time in the first cycle of PLD with or without carboplatin.
Phagocytosis measured in both MO/DC (P 5 0.85) and PMNs
(P 5 0.66) was not significantly different in patients over the
course of measurement (days 1, 3, 5, 28). The same held for
ROS (no stimulus) in both MO/DC (P 5 0.37) and PMNs (P 5
0.25) over cycle 1. On day 1, just prior to PLD administration,
the MFI of ROS (no stimulus) in all patients ranged from 7.4
to 117.05. The mean 6 S.D. MFI of ROS was 39.1 6 36.4 on
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patient 3, the mean 6 S.D. MFI for ROS of the other nine
patients was 30.5 6 25.5.
Phenotypic Probes Predict PLD PD in Patients with
EOC. All patients enrolled in the study were followed until
disease progression and/or PLD-related adverse events re-
quired discontinuation of PLD treatment. PLD could be
stopped for grade 3/4 myelosuppression, stomatitis, PPE, or
treating physician discretion. Patient 3 had rapidly pro-
gressive disease and died prior to the start of cycle 2 of PLD.
Three additional patients (1, 8, and 10) had progressive
disease while on PLD. For these four patients, the phenotypic
probes of phagocytosis (R2 5 0.77, P 5 0.02) and ROS (R2 5
0.67, P, 0.0001) prior to PLD administration were predictive
of PFS in days (data not shown). A Cox proportional hazard
model with phagocytosis as the independent variable was fit,
and we determined the predicted probability of progression-
free survival based on the level of MO/DC phagocytosis (Fig. 4)
using the three quartiles of blood phagocytosis: Q1 5 345
(MFI), med 5 486 (MFI), and Q3 5 621 (MFI).
PLD PK Predicts PD in Patients with EOC. The rela-
tionship between PLD PK and PD progression-free survival
and PPE was evaluated. There was a significant association
observed between encapsulated PLD exposure (AUC) and
PFS (days) in the four patients receiving PLD alone who
progressed while on PLD treatment (R2 5 0.88, P , 0.0001)
(data not shown). For the five patients who experienced PPE
during the course of the study, there was a nonstatistically
significant relationship between their exposure to PLD and
the highest grade of PPE reported (R2 5 0.08, P 5 0.6) (data
not shown)
Discussion
We have previously reported a relationship between physio-
logic parameters such as body weight, organ blood flow, and
monocyte count and the PK of PEGylated liposomes in animal
models and in patients with refractory solid tumors (Caron
et al., 2011). In this prior study, variability in the PK, par-
ticularly CL and exposure as measured by area under the
concentration versus time profile was noted across species.
However, this current study looks at a plausible biologic ex-
planation for the variability in PK of NP across species and in
a clinically relevant patient population. We found that the
phagocytic capacity and level of ROS production in MO/DC in
blood of mice, rats, dogs, and humans is correlated with the
CL of PEGylated liposomal agents across all species. This
finding, in addition to our prior clinical studies of PEGylated
liposomal CKD-602 (S-CKD602), prompted the development
of a second clinical study that used the same phenotypic
probes of MPS function to predict PLD PK and PD in patients
with recurrent EOC (Zamboni et al., 2009). For the first time,
we have demonstrated that a fast and inexpensive blood test
of MPS function obtained prior to the administration of PLD
can be used to predict PK, efficacy, and toxicity and can be
used to individualize therapy. These probes may also predict
PK and PD of other NP, conjugates, monoclonal antibodies,
and antibody drug conjugates in animal models and in patients
(Caron et al., 2012).
We observed a linear relationship between MPS activity
and theCL of PEGylated liposomes across species. The phagocytic
capacity and production of ROS ofMO/DCwas correlatedwith CL
of the PEGylated liposomes PLD, S-CKD602, and SPI-077.
The relationship was particularly noteworthy in MO/DC
phagocytosis with the CL of PLD (R2 5 0.92), S-CKD602
(R2 5 0.92), and SPI-077 (R2 5 0.77). This was the first study
reporting a relationship between MPS function in blood and
CL of an NP across species, including patients with cancer.
The phenotypic probes developed in this study can be used to
profile various types of NP agents in preclinical models and
patients. In addition, the probes of MPS function can be used
to determine which animal model(s) predict MPS function and
PK and PD of NP in patients.
To evaluate the interaction of NPs with the MPS in a
clinically relevant patient population and building upon our
Fig. 1. Relationship between phagocytosis (A) and production of ROS (B) in MO/DC from blood and CL of PEGylated liposomal agents in mice, rats,
dogs, and patients. The ability to translate results of NP preclinical data to human patients may require measuring cellular function of the cells
responsible for NP uptake and CL. The mean values for three species are represented by individual symbols, with diamonds as PLD, squares as
S-CKD602, and triangles as SPI-077. The species data are in vertical columns from left to right: rats, mice, dogs, and patients. The best fit line for each
group is represented by the solid lines. Across species, a positive association was observed between cell function and CL of PEGylated liposomes.
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previous findings, we performed a clinical study using
circulating MO/DC in blood as a surrogate measure of the
MPS function to predict PLD PK and PD (PFS and PPE
toxicity). Results of the study reported here demonstrate that
probes of MPS function predict PLD PK and PD. There was
a linear relationship between encapsulated doxorubicin CL
and both phagocytosis (R2 5 0.43, P 5 0.04) and ROS activity
(R2 5 0.61, P 5 0.008) in blood MO/DC.
Consistent with the association between MPS probes and
PLD PK, there was an association between phagocytosis
(R2 5 0.77, P 5 0.02) and ROS (R2 5 0.67, P 5 0.06) probes
with PFS in the four patients who progressed while on PLD
alone at the time of manuscript preparation. These results
suggest that patients with higher MPS activity have a faster
CL of PLD and a lower plasma exposure, which may be associ-
ated with less drug being available for delivery to the tumor and
lower response. This relationship is further demonstrated by
a Cox proportional hazard model that includes all 10 patients
and assesses the relationship of the phagocytosis probe and its
influence on the outcome of progression-free survival.
Our results suggest that the phenotypic probes may po-
tentially provide valuable information toward dose individual-
ization. Probes could be used to measure MPS function in each
patient before administration of PLD, and then the dose of PLD
may be adjusted based on MPS function and target plasma
exposure (AUC). This is a similar process to that used to
individualize carboplatin dose based on renal function and
target plasma AUC (Calvert et al., 1989; Egorin et al., 1994).
Fig. 2. Relationship between MO/DC function and encapsulated doxorubicin CL in patients presented in a linear regression model. Measuring
phagocytosis and production of ROS of MO/DC from patient blood samples at baseline (prior to the start of chemotherapy) was used as a phenotypic
probe of MPS function and encapsulated doxorubicin CL. Each open circle represents an individual patient, and the solid line is the regression line. (A)
Phagocytic activity (MFI) is significantly correlated with CL of encapsulated doxorubicin in 10 patients (R2 = 0.43, P = 0.04). (B) Production of reactive
oxygen species: MFI is significantly correlated with CL of encapsulated doxorubicin in 10 patients (R2 = 0.61, P = 0.008). (C) Phagocytic activity: MFI is
significantly correlated with CL of encapsulated doxorubicin in six patients receiving PLD alone (R2 = 0.57, P = 0.03). (D) Production of reactive oxygen
species: MFI is significantly correlated with CL of encapsulated doxorubicin in six patients receiving PLD alone (R2 = 0.61, P = 0.001).
TABLE 3
Ability of an oxidative burst phenotypic probe to predict PLD clearance in patients
Linear regression of the oxidative burst probes and PLD CL in the 10 patients enrolled in the study. Values are reported for patients who received
PLD (only) or PLD + carboplatin as their standard therapy for recurrent EOC.
Stimulant All Patients (R2, rs) PLD Only (R
2, rs) PLD + Carboplatin (R
2, rs)
No stimulant (baseline cell ROS production) 0.61, 0.64,‡ 0.61, 0.6,* 0.0005, 0.4
E. coli (particulate) 0.46, 0.22,* 0.44, 0.2 0.26, 0.4
fMLP (physiologic) 0.54, 0.57,* 0.48, 0.7 0.14, 0.4,‡
PMA (synthetic) 0.23, 0.72 0.21, 0.8 0.59, 0.8
fMLP, N-formyl-methionine-leucine-phenylalanine.
‡P # 0.001; *P # 0.05.
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One MPS probe also was predictive of PPE toxicity in patients,
as the ROS production at baseline was correlated with PPE
grade on a scale of 0–5 (R2 5 0.56); however, this will need to
be validated in a larger cohort of patients. If probes may be
used to determine efficacy, such as PFS, they could also indicate
early in the treatment plan whether PLD is a worthwhile
option for the particular patient.
When comparing the association between phagocytosis or
ROS phenotypic probes and encapsulated doxorubicin CL,
patient 3 consistently had the highest value in bothmeasures.
All data points were included in this study of 10 patients;
however, patient 3 noticeably improves the relationship using
simple linear regression. Interestingly, patient 3 had the most
extensive disease burden of all patients enrolled. A magnetic
resonance imaging scan taken just prior to her start on the
study indicated moderate volume ascites and multiple tumor
masses abutting the liver, the largest measuring 5.2 3.7 cm.
She was the only patient enrolled on our study with detectable
tumors in her liver. Thus, the higher MPS activity and CL of
PLD in this patient may be explained in part by the reported
relationship between tumor metastases in liver and the CL of
NP (Wu et al., 2011). Our group has previously reported that
patients with primary or metastatic tumors in their liver (n5
21) had a significantly (P5 0.02) higher CL of theNPS-CKD602
compared with individuals without tumors in their liver (n5 8)
(22). This suggests that patients with tumors in their liver may
require a higher dose of NP compared with patients without
tumors in their liver. This is a paradigm shift from what is
normally seen with small-molecule agents where patients
with tumors in their livers have a reduced CL of drugs that are
metabolized by phase I and II enzymes (Stewart et al., 1990).
One potential reason for the difference in the relationship
between encapsulated doxorubicin CL and cellular functional
assays between the PLD only and PLD in combination with
carboplatin could be secondary to platinum effects on the cel-
lular function of the MPS cells. The effect of platinum agents
on monocytes has been explored in vitro (Nielsen, 1984). In
this study, a 1 mM exposure of cisplatin for 60 minutes was
shown to selectively inhibit chemotaxis, which can then also
inhibit phagocytosis, in monocytes isolated from venous blood
of healthy volunteers (Nielsen, 1984). Fumarulo et al. (1980)
also reported an in vitro chemotaxis inhibition by cisplatin
using peritoneal macrophages of the rat. In addition, an in
vivo study has reported impaired blood monocyte chemotaxis
in cancer patients $20 hours after receiving cisplatin at
20 mg/m2 i.v.  1 (Nielsen et al., 1985). On the basis of these
studies and our results, the quick onset of chemotaxis and
phagocytosis inhibition by cisplatin could explain a lack of
functioning monocytes in the area of drug uptake and sub-
sequently a lower NP CL.
We are aware that, due to the relatively small number of
subjects in this study of PLD in patients with EOC, some of
our statistical comparisons are likely underpowered, which
may have affected our ability to detect significant relation-
ships. Nevertheless, we were able to observe suggestive as-
sociations between monocyte function and PLD CL, PFS, and
PPE toxicity in these exploratory, rather than confirmatory
analyses. Moreover, the data show that the patient with the
highest probe activity had a different pathophysiology than
the other nine patients enrolled. Not only did this patient
have the most extensive disease burden, but the highest ROS
Fig. 3. The multiple linear regression model with doxorubicin clearance
as the dependent variable and phagocytosis and treatment (an indicator
variable for PLD or PLD plus carboplatin) as independent variables.
Individual data points are represented as the symbols. The results suggest
a positive linear association between phagocytosis and CL of PLD
(bphagocytosis = 0.04, P = 0.07). The observations for the two treatment
types are denoted by x = PLD + carboplatin and open circle = PLD only.
The regression lines are displayed for the two treatment types (dotted
line = PLD + carboplatin, and solid line = PLD only). This model, which
results in two intercepts (intercept for PLD alone = b0 and intercept for
PLD plus carboplatin = b0 + btreatment) and a common slope (bphagocytosis),
suggests that patients with higher MPS function have a higher CL of PLD.
Patients on PLD + carboplatin (dotted regression line) had somewhat
lower doxorubicin clearance compared with patients on PLD only (solid
regression line); however, the treatment effect was not significant
(btreatment = 6.06, P = 0.38).
Fig. 4. Progression-free survival probability over time in days for 10
patients with recurrent EOC receiving PLD. Using the three quartiles of
blood phagocytosis [Q1 = 345 (MFI), med = 486 (MFI), and Q3 = 621
(MFI)], a Cox proportional hazard model with phagocytosis as the inde-
pendent variable can be fit to the data. The model suggests lower
progression-free survival probabilities for higher levels of phagocytosis in
MO/DC in blood.
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measurement. These results may indicate an environment of
oxidative stress and imbalanced redox systems (Elbim and
Lizard, 2009).
This study shows that the CL of PEGylated liposomes
across four different species is related to the cellular function
of MO/DC. MPS function can be easily measured using flow
cytometry and serve as a phenotypic probe to relatively non-
invasively predict the PK and PD for PLD in women with
recurrent EOC. Phenotypic probes are reproducible, highly
translatable, and readily transferable to clinical practice, as
both the cell-based assays and flow cytometry analyses are
available in hospitals and are straightforward to perform. We
demonstrated that phenotypic probes can predict PLD PK,
the PLD PK predicts PD, and ultimately that the phenotypic
probes can predict PLD PD. The ability to employ a clinical
test that is fast, inexpensive, and can be used to individualize
PLD therapy and potentially treatment with other NP agents
in patients is of great potential value. A randomized clinical
trial comparing response and toxicity of PLD in patients with
EOC treated with standard PLD based on body surface area
compared with the dose of PLD individualized based on our
MPS probes is planned.
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